Abstracts tagged "Scleroderma"

Abstract Number: 1532 • ACR Convergence 2022
The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging
sanya Chhikara¹, Adinan Kanda², mohamed Ismail², Fredrick Ogugua², Rejowana Rouf², khaled Ismail², Parag Bawaskar², Jerry Molitor² and Chetan Shenoy², ¹University of Minnesota, New York, NY, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Cardiac disease in systemic sclerosis (SSc) may be primary or secondary to coronary artery disease, pulmonary, or renal disease. The prevalence of the primary…
Abstract Number: 2164 • ACR Convergence 2022
Profibrotic Alveolar Macrophages as a Potential Biomarker in Systemic Sclerosis-associated Interstitial Lung Disease
Nikolay Markov¹, Karolina Senkow¹, Anthony Esposito², Jonathan Puchalski³, Mridu Gulati³, Erica Herzog³, Danielle Antin-Ozerkis⁴, Mary Carns⁵, Alyssa Williams⁶, Nic Page⁶, Alexander Misharin¹ and Monique Hinchcliff⁷, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Brigham and Women's Hospital, Department of Medicine, Boston, MA, ³Yale School of Medicine, New Haven, CT, ⁴Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Yale University, New Haven, CT, ⁷Yale School of Medicine, Westport, CT
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc). Previously, profibrotic monocyte-derived alveolar macrophages (MoAM) expressing (SPP1,…
Abstract Number: 0940 • ACR Convergence 2022
Effect of an 8-week Tailored Physical Therapy Program on Sexual Function in Women with Systemic Sclerosis and Idiopathic Inflammatory Myopathies: A Pilot Controlled Study
Barbora Hermankova¹, Maja Spiritovic¹, Sabina Oreska², Hana Storkanova², Karel Pavelka³, Ladislav Šenolt⁴, Jiří Vencovský⁴, Radim Becvar² and Michal Tomcik², ¹Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic rheumatic diseases like systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM) may affect all aspects of life, including sexual health. However, no non-pharmacological…
Abstract Number: 1171 • ACR Convergence 2022
Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease
Phan Saligrama¹, Erin Wilfong², Elise Rizzi³, Leslie Crofford² and Peggy Kendall¹, ¹Washington University, Saint Louis, MO, ²Vanderbilt University Medical Center, Nashville, TN, ³Pennsylvania State University, Hershey, PA
Background/Purpose: The pathogenesis of systemic sclerosis is not well understood. The key differences between immune cell compartments in scleroderma with and without interstitial lung disease…
Abstract Number: 1535 • ACR Convergence 2022
Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis
Jessica Fairley¹, Laura Ross², Alannah Quinlivan³, Dylan Hansen⁴, Elizabeth Paratz⁵, Wendy Stevens⁴, Peter M Kistler⁶, Andre La Gerche⁷ and Mandana Nikpour⁸, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ³St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, ⁴St Vincent's Hospital Melbourne, Melbourne, Australia, ⁵The Baker Institute; St Vincent's Hospital Melbourne, Melbourne, Australia, ⁶The Baker Heart and Diabetes Institute; The University of Melbourne; Monash University, Melbourne, Australia, ⁷The Baker Heart and Diabetes Institute; The University of Melbourne, Melbourne, Australia, ⁸The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Scleroderma (SSc) Heart Involvement (SHI) is an under recognised complication of SSc and may manifest as arrhythmias or sudden cardiac death(SCD). The incidence of…
Abstract Number: 2166 • ACR Convergence 2022
Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments
Eric Schwender¹, Dylan Hansen², Wendy Stevens², Laura Ross³, Nava Ferdowsi², Susanna Proudman⁴, Jenny Walker⁵, Jo Sahhar⁶, Gene-Siew Ngian⁷, Lauren Host⁸, Gabor Major⁹, Mandana Nikpour¹⁰ and Kathleen Morrisroe², ¹Royal College of Surgeons, Dublin, Ireland, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ⁴Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁵Royal Adelaide Hospital, Adelaide, Australia, ⁶Monash Health, Melbourne, Australia, ⁷Melbourne Health, Northcote, Australia, ⁸Fiona Stanley Hospital, London, United Kingdom, ⁹Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, ¹⁰The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: To characterise a cohort of Australian scleroderma patients with inflammatory arthritis including patient characteristics, autoantibody profile, therapy and impact on function and quality of…
Abstract Number: 1046 • ACR Convergence 2022
Scleroderma Heart Disease
Mohamed Talaat¹, Vivien Hsu² and Daniel Shindler³, ¹Rutgers Robert Wood Johnson University Hospital, North Brunswick, NJ, ²Rutgers-RWJ Medical School, South Plainfield, NJ, ³Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ
Background/Purpose: Scleroderma heart involvement (SHI) is the 3rd leading cause of death in systemic sclerosis (SSc) [1] following interstitial lung disease (ILD) & pulmonary arterial…
Abstract Number: 1172 • ACR Convergence 2022
Transcription Analysis of Macrophages Reveals Important Changes Induced by Systemic Sclerosis Fibroblasts
Juan-Pablo Zertuche¹, Taha Dinc², Fatima El Adili³, Giovanni Ligresti¹ and Andreea Bujor¹, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Revere, MA
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by immune system activation, endothelial dysfunction and widespread tissue fibrosis. Activation of the monocyte/macrophage…
Abstract Number: 1538 • ACR Convergence 2022
Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes
Aya abugharbyeh, Sadik Khuder and bashar Kahaleh, University of Toledo, Toledo, OH
Background/Purpose: Evidence suggest that autoimmune diseases tend to coexist at a higher rate than expected, reflecting a common pathogenetic pathway. However, data sets have shown…
Abstract Number: 2168 • ACR Convergence 2022
A Novel Pharmaco-Interventional Approach for the Treatment of Refractory Digital Ischemia in Systemic Sclerosis – Percutaneous Revascularization Combined with Intravenous Vasodilatory Therapy
Lily Romero Karam¹, Kevin Honan¹, Salman Arain¹ and Maureen Mayes², ¹University of Texas Health Science Center at Houston, Houston, TX, ²Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: The combination of Raynaud´s Phenomenon (RP) and vasculopathy, characterized by intimal proliferation and fibrosis, endothelial dysfunction, and smooth-muscle activation, can lead to severe digital…
Abstract Number: 1047 • ACR Convergence 2022
A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression
Elizabeth Volkmann¹, Holly Wilhalme¹, Grace Kim¹, Jonathan Goldin¹, Shervin Assassi², Masataka Kuwana³, Donald Tashkin¹ and Michael roth¹, ¹University of California Los Angeles, Los Angeles, CA, ²McGovern Medical School, University of Texas, Houston, TX, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of SSc-related death. While some patients respond favorably to treatment with immunosuppression, a subset of…
Abstract Number: 1175 • ACR Convergence 2022
Epigenetic Regulation of MicroRNA-126 in Scleroderma Is Associated with Upregulation of DNA Methyltransferase-1, Repression of Endothelial Nitric Oxide Synthase Expression, and Enhanced Platelet Adhesion to Endothelial Cells
Yongqing Wang and bashar Kahaleh, University of Toledo, Toledo, OH
Background/Purpose: SSc vasculopathy is characterized by endothelial injury and deficient endothelial-dependent vasodilation leading to occlusive and proliferative vascular outcomes. Platelet activation and elevated circulating platelet…
Abstract Number: 1539 • ACR Convergence 2022
Gene Expression Meta-Analysis Reveals Aging and Cellular Senescence Signatures in Scleroderma-associated Interstitial Lung Disease
Monica Yang¹, Seoyeon Lee², Jessica Neely³, Marina Sirota² and Paul Wolters², ¹UCSF, SF, CA, ²UCSF, SF, ³UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by diffuse fibrosis and vasculopathy that has potential to affect nearly every organ system. Interstitial lung…
Abstract Number: 2170 • ACR Convergence 2022
Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis
Francesco Del Galdo¹, Suiyuan Huang², Lesley-Anne Bissell³, sindhu johnson⁴, Daniel Furst⁵ and Dinesh Khanna⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ²University of Michigan, Ann Arbor, MI, ³University of Leeds, Leeds, United Kingdom, ⁴Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: The Ranked Composite Important Difference (RCID) in diffuse cutaneous Systemic Sclerosis ( dcSSc) is a clinically and patient meaningful composite score for outcome of…
Abstract Number: 1052 • ACR Convergence 2022
Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey
Darpan Thakare¹, Naveen R¹, John Pauling², Sakir Ahmed³, Chris Wincup⁴, Nicolletta Del Papa⁵, Gianluca Sambataro⁶, Fabiola Atzeni⁷, Marcello Govoni⁸, SIMONE PARISI⁹, Elena Bartoloni Bocci¹⁰, Gian Domenico Sebastiani¹¹, Enrico Fusaro¹², Marco Sebastiani¹³, Luca Quartuccio¹⁴, Franco Franceschini¹⁵, Pier Paolo Sainaghi¹⁶, Giovanni Orsolini¹⁷, Rossella De Angelis¹⁸, Maria Giovanna Danielli¹⁹, Vincenzo Venerito²⁰, Parikshit Sen²¹, Minchul Kim²², Abraham Edgar Gracia-Ramos²³, Akira Yoshida²⁴, James B. Lilleker²⁵, Vishwesh Agarwal²⁶, Sinan Kardes²⁷, Jessica Day²⁸, Marcin Milchert²⁹, Mrudula Joshi³⁰, Tamer A Gheita³¹, Babur Salim³², Ioannis Parodis³³, Albert Selva O’Callaghan³⁴, Elena Nikiphorou³⁵, Tulika Chatterjee²², Ai Lyn Tan³⁶, Arvind Nune³⁷, Lorenzo Cavagna³⁸, Samuel Shinjo³⁹, Nelly Ziade⁴⁰, Johannes Knitza⁴¹, Hector Chinoy⁴², Oliver Distler⁴³, Masataka Kuwana⁴⁴, Rohit Aggarwal⁴⁵, Latika Gupta⁴⁶, Vikas Agarwal¹ and Ashima Makol⁴⁷, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²North Bristol NHS Trust, Bristol, United Kingdom, ³Kalinga Institute of Medical Sciences, Bhubaneswar, India, ⁴Rayne Institute, University College London, London, United Kingdom, ⁵Unità operativa complessa (UOC) Day Hospital Reumatologia via Gaetano Pini 9, Centro Specialistico Ortopedico Traumatologico, Gaetano Pini-CTO,, Milano, ⁶Medico Immunologia e reumatologia presso, Artoreuma S.R.L., Cors S, Mascalucia, ⁷Rheumatology Unit, University of Messina, Messina, Italy, ⁸S. Anna Hospital and University of Ferrara, Ferrara, Italy, ⁹Italian Society for Rheumatology, Turin, Italy, ¹⁰Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ¹¹U.O.C. Reumatologia, Ospedale San Camillo-Forlanini,, Roma, ¹²Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ¹³Azienda Policlinico di Modena, Modena, Italy, ¹⁴Department of Medicine (DAME), ASUFC, University of Udine, Udine, ¹⁵Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹⁶IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy, ¹⁷Department of Medicine, Rheumatology Unit, University of Verona, Verona, Verona, ¹⁸Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Marche, Italy, ¹⁹Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle, Marche, Italy, ²⁰Department of Emergency and Organ Transplantations-Rheumatology Unit, University of Bari "Aldo Moro", Bari, Italy, ²¹Maulana Azad Medical College, New Delhi, India, ²²University of Illinois College of Medicine Peoria, Peoria, IL, ²³Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ²⁴Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ²⁵The University of Manchester, Manchester, United Kingdom, ²⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ²⁷Istanbul University, Istanbul, Turkey, ²⁸Walter and Eliza Hall Institute, Melbourne, Australia, ²⁹Pomeranian Medical University in Szczecin, Szczecin, Poland, ³⁰Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ³¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ³²Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ³³Karolinska Institutet, Stockholm, Sweden, ³⁴Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³⁵Leiden University Medical Center & King's College London, London, United Kingdom, ³⁶University of Leeds, Leeds, United Kingdom, ³⁷Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ³⁸Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ³⁹Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ⁴⁰Saint-Joseph University, Beirut, Lebanon, ⁴¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴²The University of Manchester, Sale, United Kingdom, ⁴³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴⁴Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴⁶Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ⁴⁷Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Dedicated data on COVID-19 vaccine-related adverse events (ADEs) in patients with systemic sclerosis (SSc) is limited. Therefore, we aimed to compare all patient-reported ADEs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].